Categories
Change Password!
Reset Password!
Timely initiation of oral Valganciclovir, alongside good nutrition and a brief cholestasis duration, optimizes recovery in infants with CMV-induced intrahepatic cholestasis, showcasing its effectiveness and safety.
A recent study in ‘Pediatric Gastroenterology, Hepatology and Nutrition’ centred around the effectiveness of oral Valganciclovir in treating cytomegalovirus (CMV) infection in infants suffering from intrahepatic cholestasis, demonstrating significant benefits with minimal side effects.
CMV infection poses a serious risk to various organs, leading to high mortality rates and lasting complications, including acute or chronic hepatitis and even cirrhosis.
Valganciclovir was evaluated in this study by Salahuddin Mahmud et al. for its impact on the clinical, biochemical, and virological outcomes in babies diagnosed with congenital CMV infection.
A total of 20 infants under six months of age diagnosed with congenital CMV and exhibiting intrahepatic cholestasis were included. Participants were randomly allocated to two groups: one received supportive care alone, while the other was treated with Valganciclovir 16 mg/kg orally, administered twice every day for 6 weeks alongside supportive therapies.
Assessments conducted at diagnosis, 6 weeks, and 6 months disclosed a notable decrease in clinical symptoms such as jaundice, dark urine, and pale stools, as well as significant improvements in laboratory parameters including bilirubin levels and liver enzymes in the Valganciclovir-treated group. In contrast, the control group showed little to no change in their condition. Oral Valganciclovir could be a vital treatment option for infants battling CMV (largest member of herpes virus family) infection with intrahepatic cholestasis, as concluded.
Pediatric Gastroenterology, Hepatology and Nutrition
Efficacy and Safety of Valganciclovir in Congenital Cytomegalovirus Infection with Isolated Intrahepatic Cholestasis: A Randomized Controlled Trial
Salahuddin Mahmud et al.
Comments (0)